Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Acadia Pharmaceuticals Inc shares valued at $14,420 were sold by Schneyer Mark C. on Jun 10 ’24. At $14.79 per share, Schneyer Mark C. sold 975 shares. The insider’s holdings dropped to 34,564 shares worth approximately $0.57 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, DAVIS STEPHEN sold 11,427 shares, netting a total of over 193,573 in proceeds. Following the sale of shares at $16.94 each, the insider now holds 155,231 shares.
Before that, Schneyer Mark C. had sold 3,503 shares from its account. In a trade valued at $59,341, the EVP, CHIEF FINANCIAL OFFICER traded Acadia Pharmaceuticals Inc shares for $16.94 each. Upon closing the transaction, the insider’s holdings decreased to 3,503 shares, worth approximately $0.52 million.
As published in their initiating research note from BMO Capital Markets on June 27, 2024, Acadia Pharmaceuticals Inc [ACAD] has been an Outperform and the price target has been revised to $31. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in mid March. As of March 12, 2024, Mizuho has decreased its “Buy” rating to a “Neutral” for ACAD. Earlier on January 30, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ACAD stock.
Analyzing ACAD Stock Performance
During the last five days, there has been a surge of approximately 10.98%. Over the course of the year, Acadia Pharmaceuticals Inc shares have dropped approximately -47.72%. Shares of the company reached a 52-week high of $31.82 on 01/02/24 and a 52-week low of $14.55 on 06/10/24. A 50-day SMA is recorded $15.75, while a 200-day SMA reached $21.77. Nevertheless, trading volume fell to 1.81 million shares from 1.89 million shares the previous day.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 15.84, which, if violated, would cause prices to drop to 15.32. In the upper region, resistance lies at 16.71. The next price resistance is at 17.05. RSI (Relative Strength Index) is 61.75 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.59, which suggests the price will decrease in the coming days. Percent R is at 8.00%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
